Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 1201 • 2018 ACR/ARHP Annual Meeting
Finger Extensor Tendon Involvement Is Frequent in Early Rheumatoid Arthritis
Mihaela Maruseac¹, Patrick Durez^2,3, Adrien Nzeusseu Toukap⁴ and Maria Stoenoiu⁵, ¹Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, ⁴Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁵Rheumatology, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Finger extensor involvement (FET) at ultrasound examination (US) was previously described in patients suffering from early psoriatic arthritis. Contradictory results were published in patients…
Abstract Number: 1457 • 2018 ACR/ARHP Annual Meeting
Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Peter M. ten Klooster^1,2, Laura M.M. Steunebrink³, Letty Versteeg⁴, Inmaculada de la Torre⁵, Francesco de Leonardis⁶, Walid Fakhouri⁶, Liliana Zaremba-Pechmann⁶ and Mart van de Laar^1,3, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ³Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁴Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁵Eli Lilly and Company, Madrid, Spain, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Recent studies suggested a disconnect between disease activity and radiographic damage in rheumatoid arthritis (RA) patients treated with more aggressive treatment (1). Therefore, the…
Abstract Number: 1483 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients
Giampaolo Giacovelli, Beatrice Barbetta, Cristina Vitalini, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: Rheumatoid arthritis patients positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (ACPA) are considered to manifest an aggressive disease course compared with…
Abstract Number: 1485 • 2018 ACR/ARHP Annual Meeting
Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia
Malin C Erlandsson^1,2, Minna Turkkila³, Rille Pullerits^2,3,4 and Maria I Bokarewa^2,3, ¹Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, ²Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, ⁴Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Background/Purpose: Early recognition of rheumatoid arthritis (RA) is believed to be the key to successful treatment of this disease. Symptoms of arthralgia often predate development…
Abstract Number: 1486 • 2018 ACR/ARHP Annual Meeting
Incidence of Subclinical Signs of Inflammation in Patients with New Onset of Non-Specific Musculoskeletal Symptoms and Anti-Citrullinated Peptide Positivity: First Interims Analysis of the Panora Trial
Michaela Koehm^1,2, Ulf Henkemeier^2,3, Tanja Rossmanith², Stephanie Dauth², Timm Oberwahrenbrock², Ann Christina Foldenauer², Karola Mergenthal⁴, Harald Burkhardt^2,3,5 and Frank Behrens^2,3,5, ¹Division of Rheumatology Goethe-University Frankfurt, Frankfurt/Main, Germany, ²Fraunhofer IME Branch for Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ³Centre of Innovative Diagnostics and Therapeutics Rheumatology / Immunology at University Hospital Goethe-University Frankfurt, Frankfurt, Germany, ⁴Institute for General Practice Goethe-University, Frankfurt, Germany, ⁵Division of Rheumatology Goethe-University Frankfurt, Frankfurt, Germany
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease affecting approx. 1% of the adult population of Northern Europe and North America. Strategies for…
Abstract Number: 1488 • 2018 ACR/ARHP Annual Meeting
Identification of Joint Locations That Are Poor Prognostic in an Early Seropositive Erosive RA Cohort
Patrick Durez¹, Sofie Robert², Alexandra Thiry³ and Harris A Ahmad³, ¹Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Bristol-Myers Squibb, Braine L’Alleud, Belgium, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Patients (pts) with early RA often present with multiple and different areas of joint involvement. While the ACR and EULAR guidelines specify high disease…
Abstract Number: 1424 • 2017 ACR/ARHP Annual Meeting
Impact of Glucocorticoid Therapy on the Efficacy of SC Abatacept or Adalimumab in RA Patients with Inadequate Response to MTX: A Post Hoc Analysis of Data from a Head-to-Head Trial
Yannick Degboé^1,2, Michael Schiff³, Michael Weinblatt⁴, Roy Fleischmann⁵, HA Ahmad⁶ and Arnaud Constantin^2,7, ¹Toulouse University Hospital, Toulouse, France, ²Université Paul Sabatier, Toulouse, France, ³University of Colorado, Denver, CO, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Purpan University Hospital, Toulouse, France
Background/Purpose: In patients with RA, low-dose glucocorticoids (GCs) have been shown to increase clinical, functional and radiographic efficacy when combined with conventional synthetic DMARDs;1 however,…
Abstract Number: 1445 • 2017 ACR/ARHP Annual Meeting
Effect of Methotrexate (MTX), and MTX Plus Colchicine (CCH) on the Expression and Activity of NLRP3 Inflammasome in Patients with Early Rheumatoid Arthritis (RA)
Dolores Ramos-Bello¹, Crisol Alvarez-Quiroga², Georgina Aguilera Barragán-Pickens³, Angel Javier Pedro Martínez³, Tania Adriana Luna-Zúñiga³, Georgina Martínez-Flores³, Eduardo Saul Acevedo-Castañeda⁴, Homero López-Ferretis³, Enrique Cuevas-Orta³, Eva Santillan-Guerrero³, Ricardo Moreno-Valdez³, Martín Saldaña-Baarnard³, Marco Ulises Martinez-Martinez⁵, David Herrera Van Oostdam⁶, Roberto González-Amaro⁷ and Carlos Abud-Mendoza⁸, ¹Reumatología, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosi, Mexico, ²División de Medicina Molecular y Traslacional, Centro de Investigación en Ciencias de la Salud y Biomedicina, UASLP, San Luis Potosí, Mexico, ³Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ⁴Medicina Interna, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ⁵Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ⁶Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁷Inmunología, Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ⁸Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
Background/Purpose: NLRP3 inflammasome is an intracellular protein complex involved in the production of pro-inflammatory cytokines as IL-1β and IL-18, which has been reported to have…
Abstract Number: 122 • 2017 ACR/ARHP Annual Meeting
Poor Prognostic Factors at the Start of Methotrexate Therapy Are Not Associated with Worse Treatment Response: Results from the Rheumatoid Arthritis Medication Study
JM Gwinnutt¹, Kimme L. Hyrich¹, M Lunt¹, Darren Plant¹, M Brazil², R Postema², Anne Barton¹ and Suzanne M Verstappen¹, ¹Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Bristol-Myers Squibb, Uxbridge, United Kingdom
Background/Purpose: As anti-citrullinated protein antibody positivity (+), RF+ and erosions are independently associated with poor outcomes in patients (pts) with RA, clinicians may use these…
Abstract Number: 1465 • 2017 ACR/ARHP Annual Meeting
Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada
J Foo¹, JM Rodriguez Heredia², C Polanco Sánchez³, M Mtibaa⁴, KH Herrmann⁵, E Alemao⁶, R Postema⁷ and C Baerwald⁸, ¹Mapi Group, Houten, Netherlands, ²Hospital Universitario de Getafe, Madrid, Spain, ³Bristol-Myers Squibb, Madrid, Spain, ⁴Bristol-Myers Squibb, Montréal, QC, Canada, ⁵Bristol-Myers Squibb, Munich, Germany, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁸University Hospital, Department of Internal Medicine, Rheumatology Unit, Leipzig, Germany
Background/Purpose: RA is a chronic, inflammatory disorder leading to disability and reduced quality of life. Effective treatment with biologic DMARDs poses a significant economic burden.…
Abstract Number: 235 • 2017 ACR/ARHP Annual Meeting
MRI in Rheumatoid Arthritis: Does Quantifying the Number of Erosive Lesions Improve Detection of Subtle Erosive Progression Compared to the Omeract RA MRI Scoring System?
Ulf Sundin¹, Anna-Birgitte Aga², Tore K Kvien³, Siri Lillegraven⁴ and Espen A. Haavardsholm⁴, ¹*Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Early detection of erosive progression is an important application of MRI in RA. For research purposes the OMERACT Rheumatoid Arthritis MRI Scoring system (RAMRIS)…
Abstract Number: 1820 • 2017 ACR/ARHP Annual Meeting
Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years
Veerle Stouten¹, Johan Joly², Diederik De Cock¹, Sofia Pazmino¹, Kristien Van der Elst^2,3, René Westhovens^1,2 and Patrick Verschueren^1,2, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Remission induction with methotrexate (MTX) and a moderate-dose, step-down scheme of Glucocorticoids (GC), (COBRA Slim strategy), showed equally high remission rates at year 1…
Abstract Number: 408 • 2017 ACR/ARHP Annual Meeting
CR6086 Is Highly Effective and Improves Methotrexate Effect in a Mouse Model of Rheumatoid Arthritis
Gianfranco Caselli¹, Flora Ferrari¹, Eleonora Comi¹, Marco Perrella¹, Camilla Recordati², Adriana Grotti¹, Rosanna Cavagnoli¹, Marco Lanza¹ and Lucio C. Rovati³, ¹Rottapharm Biotech, Monza, Italy, ²Mouse & Animal Pathology Lab,, Fondazione Filarete, Milano, Italy, Milano, Italy, ³Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086, a selective EP4 antagonist, dose-dependently improves disease features in rheumatoid arthritis (RA) models in rodents. Indeed, recent studies highlight the role of the…
Abstract Number: 1901 • 2017 ACR/ARHP Annual Meeting
Unfavorable Body Composition Already at the Onset of Clinical Arthritis
Samina A. Turk^1,2, Dirkjan van Schaardenburg^3,4, Maarten Boers^4,5, Sylvia de Boer¹, Cindy Fokker¹, Willem F. Lems^4,5 and Michael Nurmohamed^1,5, ¹Rheumatology, Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: An unfavorable body composition is often present in chronic arthritis patients. This unfavorable composition is a loss of muscle mass (sarcopenia), with a stable…
Abstract Number: 443 • 2017 ACR/ARHP Annual Meeting
Methotrexate Treatment Strategies in an Early Rheumatoid Arthritis Cohort
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institute de Rheumatologie, Montreal, QC, Canada, ¹⁰Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is recommended as part of initial therapy in early RA, but practices range widely. The objective of this analysis was to describe…

« Previous Page
1
…
3
4
5
6
7
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].